Clinical Trial Update: Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating a neoantigen vaccine therapy for Diffuse Intrinsic Pontine Glioma (H3.3-K27M) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Intrinsic Pontine Glioma

Drugs mentioned

• Neoantigen vaccine therapy targeting H3.3-K27M DIPG

Snippet

Sponsor: Yang Zhang | Conditions: Diffuse Intrinsic Pontine Glioma | Phase 1 | Status: COMPLETED